Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Renal, and Fibrotic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AGTR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen/Protein | AGTR1 Extracellular Loop / Membrane Extract & ECD Protein (aa1-35): High purity (>95%), Endotoxin <1EU/ug. Full-length GPCR in native membrane context available via stable cell line particles. | View AGTR1 Products |
| Gene Delivery | AGTR1 Lentivirus Premade Particles (Full-length ORF for stable cell lines. HEK293 expressed, sequence verified. Native glycosylation and membrane topology preserved. Cell-based assays are the only way to preserve GPCR conformation.) | View AGTR1 Products |
| Detection Antibody | Anti-AGTR1 Monoclonal Antibody (Recombinant positive control for Flow Cytometry, Western Blot, and receptor occupancy assays.) | View AGTR1 Products |
| Validator | AGTR1 siRNA Set (For knockdown verification and assay specificity controls.) | View AGTR1 Products |
| Related Target: AGTR2 | Receptor subtype counter-screening and selectivity validation. | View AGTR2 Products |
| Related Target: ACE2 | Upstream RAAS pathway modulator and synergistic therapeutic target. | View ACE2 Products |
| Related Target: AGT | Upstream precursor protein; validation tool for RNAi-mediated pathway inhibition. | View AGT Products |
| Related Target: ACE | Processing enzyme; pathway modulation and enzymatic assay standards. | View ACE Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Transmembrane Conformation (GPCR) | High-titer Lentivirus Premade Particles for native membrane expression in HEK293/CHO, preserving native glycosylation and post-translational modifications. |
| Subfamily Counter Screening (AGTR1 vs AGTR2) | Paired AGTR1 and AGTR2 stable cell lines for orthogonal counter-screening under identical assay conditions. Homologs verified by mass spec. |
| Lack of Controls | Clinical Benchmark Antibodies included for FACS and cellular binding assays. |
| False Positives | Validated siRNA included for receptor-specific knockdown confirmation and assay de-risking. |
| Cross-species Toxicology (Cyno/Mouse/Rat) | Human/Cyno/Mouse ortholog ORF clones and stable cell lines available with sequence identity confirmation (>95%). |
| Pharmacogenomic Variant Screening | A1166C polymorphism mutant ORF available for personalized medicine and resistance mechanism assays. |
| Biased Signaling Detection (G-protein vs β-arrestin) | Human WT AGTR1 lentivirus with calcium flux validated; mutant variants available for mechanism-of-action studies. |
Live AGTR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The AGTR1 therapeutic space remains dominated by small-molecule ARBs, yet the innovation frontier is shifting toward biased ligand pharmacology, fixed-dose combination therapies (e.g., ARNI), and tissue-specific targeting. Notable developments include the clinical success of Entresto and emerging biased agonists like TRV027. The neutralization of pathogenic AGTR1 autoantibodies (AT1R-AA) in transplant rejection and preeclampsia represents a growing diagnostic and therapeutic area. Next-generation programs exploit structural differences between AGTR1 and AGTR2 to improve cardiorenal safety margins, while emerging fibrosis and oncology indications demand novel high-throughput cell-based assays. As first-generation therapies for hypertension and heart failure reach full maturity, the next wave of R&D is aiming at selective pathway modulation (e.g., beta-arrestin vs. Gq signaling) and upstream pathway inhibition via RNAi targeting angiotensinogen (AGT).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule ARB | Novartis, AstraZeneca, Daiichi Sankyo, Takeda | Hypertension, Heart Failure, Chronic Kidney Disease | Radioligand displacement & Calcium-flux on AGTR1 stable cells; AGTR2 selectivity panel |
| Biased Agonist/Ligand | Trevena, Novartis, Academic/Biotech Consortiums | Acute Heart Failure, Cardioprotection, Fibrosis | Signaling Bias Assay (G-protein vs β-arrestin) using WT and mutant AGTR1 lentivirus lines |
| Autoantibody Trap | Academic/Diagnostics | Transplant Rejection, Preeclampsia | Epitope Screening using native-conformation AGTR1-expressing cells |
| Combination Therapy (ARNI) | Novartis, AstraZeneca | Heart Failure, Resistant Hypertension | Pathway interaction assays (AGTR1 + Neprilysin co-expression systems) |
| RNAi (Upstream AGT) | Alnylam/Roche, Novartis | Refractory Hypertension | AGTR1 knockdown validation (siRNA and rescue constructs); AGTR1 expression as PD biomarker |
| Macromolecular Antagonist | Preclinical / Vaccine Programs | Resistant Hypertension | Receptor internalization & immunogenicity assays using AGTR1-overexpressing lines |
Cross-Selling Target Recommendations
- AGTR2: Counter-regulatory receptor; essential for selectivity counter-screening in AGTR1 programs.
- ACE2: Cardioprotective carboxypeptidase that counterbalances AGTR1; key in COVID-19 and cardiorenal research.
- AGT: Upstream precursor targeted by RNAi therapies (e.g., zilebesiran); AGTR1 expression serves as downstream efficacy readout.
- ACE: Processing enzyme in the RAAS cascade; needed for full pathway reconstitution studies.
Key Mutations & Variants
Well-documented AGTR1 variants relevant to drug discovery include:
- rs12721226 (UniProt P30556 VAR_029206)
- rs17852013 (UniProt P30556 VAR_070375)
- rs12721225 (UniProt P30556 VAR_029207)
- A1166C polymorphism: Known to affect ARB response and cardiovascular disease prognosis; mutant ORF available for pharmacogenomic assays.